Hager Investment Management Services LLC Takes $33,000 Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Hager Investment Management Services LLC acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 535 shares of the company’s stock, valued at approximately $33,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Yousif Capital Management LLC raised its position in TransMedics Group by 14.6% during the fourth quarter. Yousif Capital Management LLC now owns 12,954 shares of the company’s stock valued at $808,000 after buying an additional 1,652 shares during the period. Guidance Capital Inc. grew its stake in TransMedics Group by 54.5% during the 4th quarter. Guidance Capital Inc. now owns 3,642 shares of the company’s stock valued at $222,000 after acquiring an additional 1,284 shares in the last quarter. Tempus Wealth Planning LLC acquired a new position in shares of TransMedics Group in the 4th quarter valued at about $346,000. Jennison Associates LLC purchased a new stake in shares of TransMedics Group in the fourth quarter worth approximately $555,000. Finally, CENTRAL TRUST Co lifted its position in shares of TransMedics Group by 162.2% in the fourth quarter. CENTRAL TRUST Co now owns 1,442 shares of the company’s stock worth $90,000 after purchasing an additional 892 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Wednesday. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. TD Cowen reduced their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Canaccord Genuity Group lowered their target price on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Finally, Robert W. Baird cut their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Stock Up 3.4 %

Shares of TMDX stock opened at $74.57 on Thursday. The company has a market capitalization of $2.50 billion, a price-to-earnings ratio of 79.33 and a beta of 2.12. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock’s 50 day simple moving average is $66.92 and its 200 day simple moving average is $110.67. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37.

Insider Transactions at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of TransMedics Group stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 7.00% of the stock is owned by corporate insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.